Full Title
An Open-Label, First-in-Human, Phase 1/2 Dose Escalation and Expansion Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell CarcinomaPurpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Martin Voss’ office at 646-888-4716.
Protocol
26-080
Phase
Phase I/II (phases 1 and 2 combined)
Disease Status
Newly Diagnosed & Relapsed/Refractory
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT07300241